PDF(1318 KB)
诊断横纹肌肉瘤的一个Li-Fraumeni综合征家系报道并文献复习
谢瑶, 赵卫红, 华瑛, 孙青, 吴鹏辉
中国当代儿科杂志 ›› 2017, Vol. 19 ›› Issue (12) : 1263-1266.
PDF(1318 KB)
PDF(1318 KB)
诊断横纹肌肉瘤的一个Li-Fraumeni综合征家系报道并文献复习
A rhabdomyosarcoma patient from a Li-Fraumeni syndrome family:a case report and literature review
Li-Fraumeni综合征（LFS）为一种遗传易感肿瘤综合征，肿瘤发病年龄早，个体肿瘤发生率高。先证者为2岁6个月男童，病理诊断为左颌下胚胎型横纹肌肉瘤；其哥哥因横纹肌肉瘤去世，外祖母患乳腺癌。对患儿及部分家庭成员进行TP53基因突变检测，发现患儿存在EXON 8的错义突变：c.844C > T（p.Arg282Trp）（杂合），患儿母亲、姐姐均检测出该突变。符合LFS诊断标准。TP53基因是比较明确的LFS致病基因。儿童患者LFS疾病谱系中最常见的依次为骨肉瘤、肾上腺皮质癌、中枢神经系统肿瘤及软组织肿瘤，其它可能相关的包括白血病、淋巴瘤等。LFS患者有较大的几率患二次甚至多次肿瘤。因此对于儿童肿瘤患者，尤其是某些具有遗传易感性的肿瘤，有必要进行遗传学评估，如果存在TP53基因突变，治疗上则应当更为积极，并对LFS家系进行系统监测管理。
Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome, with the characteristics of early onset of cancer and high cancer incidence. TP53 is widely accepted as a pathogenic gene of LFS. A 2 years and 6 months old boy is reported in this article, who was diagnosed with embryonal rhabdomyosarcoma (RMS) in the left submandibular region. His brother died of RMS, and his grandmother was diagnosed with breast cancer. TP53 gene mutation detection was performed in this patient and some family members, indicating a missense mutation in exon 8 of the patient:c.844C > T (p.Arg282Trp, heterozygous). TP53 mutation was also found in his mother and sister. The boy met the diagnostic criteria for LFS. Among pediatric patients, the most common LFS diseases include osteosarcoma, adrenocortical cancer, central nervous system tumor, and soft tissue tumor. Additionally, leukemia and lymphoma are also involved. LFS patients have a high risk to suffer secondary or even multiple cancers. Therefore, it is necessary to perform genetic detection for pediatric cancer patients, especially those with hereditary predisposition cancers. TP53 mutation often indicates poor prognosis, so it is important to take active treatment and systematic monitoring for LFS family.
肿瘤 / 遗传 / TP53基因 / Li-Fraumeni综合征 / 儿童
Cancer / Genetics / TP53 gene / Li-Fraumeni syndrome / Child
[1] Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome[J]. Ann Intern Med, 1969, 71(4):747-752.
[2] Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome:mutation detection rate and relative frequency of cancers in different familial phenotypes[J]. J Med Genet, 2010, 47(6):421-428.
[3] Evans DG, Birch JM, Narod SA. Is CHEK2 a cause of the Li-Fraumeni syndrome?[J]. J Med Genet, 2008, 45(1):63-64.
[4] Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma[J]. Cancer, 2013, 119(2):332-338.
[5] 杨晓晨, 胡震, 吴炅, 等. 中国乳腺癌高风险人群中TP53基因胚系突变的研究[J]. 中华医学遗传学杂志, 2015, 32(6):761-765.
[6] Hu H, Liu J, Liao X, et al. Genetic and functional analysis of a Li Fraumeni syndrome family in China[J]. Sci Rep, 2016, 6:20221.
[7] Garber JE, Goldstein AM, Kantor AF, et al. Follow-up study of twenty-four families with Li-Fraumeni syndrome[J]. Cancer Res, 1991, 51(22):6094-6097.
[8] Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds[J]. Cancer Res, 1988, 48(18):5358-5362.
[9] Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li-Fraumeni syndrome[J]. J Clin Oncol, 2009, 27(26):e108-109.
[10] Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers[J]. J Clin Oncol, 2015, 33(21):2345-2352.
[11] Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia[J]. J Clin Oncol, 2011, 29(23):3185-3193.
[12] Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes:correlation between tumor type, family structure, and TP53 genotype[J]. Cancer Res, 2003, 63(20):6643-6650.
[13] Wasserman JD, Novokmet A, Eichler-Jonsson C, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma:a children's oncology group study[J]. J Clin Oncol, 2015, 33(6):602-609.
[14] Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome[J]. J Natl Cancer Inst, 1998, 90(8):606-611.
[15] Izawa N, Matsumoto S, Manabe J, et al. A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the p53 tumor-suppressor gene[J]. Int J Clin Oncol, 2008, 13(1):78-82.
[16] Kratz CP, Achatz MI, Brugières L, et al. Cancer Screening Recommendations for individuals with Li-Fraumeni syndrome[J]. Clin Cancer Res, 2017, 23(11):e38-e45.
[17] Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome:11 year follow-up of a prospective observational study[J]. Lancet Oncol, 2016, 17(9):1295-1305.
[18] Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome:a prospective observational study[J]. Lancet Oncol, 2011, 12(6):559-567.
[19] Alderfer MA, Lindell RB, Viadro CI, et al. Should Genetic Testing be Offered for Children? The perspectives of adolescents and emerging adults in families with Li-Fraumeni Syndrome[J]. J Genet Couns, 2017, 26(5):1106-1115.
[20] Ballinger ML, Mitchell G, Thomas DM. Surveillance recommendations for patients with germline TP53 mutations[J]. Curr Opin Oncol, 2015, 27(4):332-337.
[21] Daly MB, Pilarski R, Berry M, et al. NCCN Guidelines Insights:Genetic/Familial High-Risk Assessment:Breast and Ovarian, Version 2.2017[J]. J Natl Compr Canc Netw, 2017, 15(1):9-20.
[22] McBride KA, Ballinger ML, Killick E, et al. Li-Fraumeni syndrome:cancer risk assessment and clinical management[J]. Nat Rev Clin Oncol, 2014, 11(5):260-271.
北京大学第一医院青年基金（2017QN03）。
